

# CANADIAN GUIDELINES ON SEXUALLY TRANSMITTED INFECTIONS (2008 UPDATE)

## IV – MANAGEMENT AND TREATMENT OF SPECIFIC SYNDROMES

### PELVIC INFLAMMATORY DISEASES (PID) (January 2008)

#### References

1. Eschenbach DA. Epidemiology and diagnosis of acute pelvic inflammatory disease. *Obstet Gynecol* 1980; 55(suppl 5):142S–152S.
2. Aral SO, Mosher WD, Cates W Jr. Self-reported pelvic inflammatory disease in the United States, 1988. *JAMA* 1991; 266:2570–2573.
3. Westrom L, Joesoef MJ, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. *Sex Transm Dis* 1992;19:185–192.
4. Kahn JG, Walker CK, Washington AE, Landers DV, Sweet RL. Diagnosing pelvic inflammatory disease: a comprehensive analysis and considerations for developing a new model. *JAMA* 1991; 266:2594–2604.
5. Wolner-Hanssen P. Diagnosis of pelvic inflammatory disease. In: Landers DV, Sweet RL, eds. *Pelvic Inflammatory Disease*. New York, NY: Springer-Verlag; 1997: 60–75.
6. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. *Am J Med* 1983;74:14–22.
7. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. *Am J Obstet Gynecol* 2002; 186:929–937.
8. Walker CK, Kahn JG, Washington AE, Peterson HB, Sweet RL. Pelvic inflammatory disease: meta-analysis of antimicrobial regimen efficacy. *J Infect Dis* 1993;168:969–978.
9. Martens MG, Gordon S, Yarborough DR, Faro S, Binder D, Berkeley A. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Ambulatory PID research Group. *South Med J* 1993;86:604–10.
10. Arredondo JL, Diaz V, Gatian H, et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease. *Clin Infect Dis* 1997; 24:170–8.
11. Ross JDC, Cronje S, Paskowski T, et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. *Sex Trans Infect* 2006; 82:446–51.
12. Haggerty CL, Ness RB. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. *Clin Infect Dis* 2007; 44:953–60.
13. Sweet RL, Schachter J, Landers DV, Ohm-Smith M, Robbie MO. Treatment of hospitalized patients with acute pelvic inflammatory disease: comparison of cefotetan plus doxycycline and cefoxitin plus doxycycline. *Am J Obstet Gynecol* 1988;158:736–741.
14. Matsuda S. Clinical study of levofloxacin (LVFX) on the infectious diseases in the field of obstetrics and gynecology. *Chemotherapy* 1992;40:311–323.
15. Walker CK, Workowski KA, Washington AE, Soper D, Sweet RL. Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention’s guidelines for treatment of sexually transmitted diseases. *Clin Infect Dis* 1999; 28(suppl 1):S29–S36.

16. Peipert JF, Sweet RL, Walker CK, Kahn J, Reilly-Gauvin K. Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis). *Infect Dis Obstet Gynecol* 1999; 7:138–144.
17. Cunningham FG, Hauth JC, Strong JD, et al. Evaluation of tetracycline or penicillin and ampicillin for treatment of acute pelvic inflammatory disease. *N Engl J Med* 1977; 296:1380–1383.
18. Korn AP, Landers DV, Green JR, Sweet RL. Pelvic inflammatory disease in human immunodeficiency virus-infected women. *Obstet Gynecol* 1993; 82:765–768.
19. Barbosa D, Macasaet M, Brockmann S, Sierra MF, Xia Z, Duerr A. Pelvic inflammatory disease and human immunodeficiency virus infection. *Obstet Gynecol* 1997;89:65–70.